Prostate cancer incidence is highest in developed nations, compared to less-developed countries, a difference that is only partially explained by the higher use of prostate specific antigen (PSA) as a screening tool in developed nations (Center et al., 2012). This evidence concerns the gene KLK3 and prostate cancer.